JAMA examines online sales of unapproved retatrutide and zenagamtide, Icotyde holds psoriasis clearance at two years, and melflufen reaches brain tumors.
Read digest →Meals or an app slowed regain after people stopped GLP-1s, GLP-1s tracked with fewer falls in veterans, and a Melanotan II user got a new melanoma.
Read digest →Zealand's petrelintide cuts weight up to 9.2% in type 2 diabetes, WHO advises against obesity drugs under age 10, and SurVaxM misses its survival goal.
Read digest →Lilly and Novo bring GLP-1 aging data to ARDD 2026, AI-designed gut peptides cut weight in rats, and Penn maps an amylin brain circuit.
Read digest →Safiglipron's Phase 3 trial against dapagliflozin is published, elamipretide restores fertility in aged mice, and Lancet papers examine GLP-1s in women.
Read digest →J&J's oral peptide Icotyde holds psoriasis clearance at two years, REMODEL probes how semaglutide protects kidneys, and Rhode Island Medicaid drops coverage.
Read digest →Lilly's indirect comparison favors Zepbound over Wegovy HD under one estimand, and a study at EADV links GLP-1 use with more reported nail and hair problems.
Read digest →ADA and EASD publish their 2026 type 2 diabetes consensus, ribupatide cuts weight up to 20% in women with PMOS, and Vyepti helps after CGRP failure.
Read digest →Foundayo meets its heart-safety goal against insulin glargine, survodutide dropouts weigh on Zealand, and CVS Caremark's Zepbound coverage returns.
Read digest →Full retatrutide TRIUMPH-2 data land at EASD, Lilly's EloraTZP tops tirzepatide alone in Phase 2b, and Saudi Arabia moves against online peptide sellers.
Read digest →Novo pays $300M upfront for Hengrui's oral HRS-1596, petrelintide Phase 2 data are published, and a Nordic study finds no semaglutide-pancreatic cancer link.
Read digest →Roche drops emugrobart after a Phase 2 interim look, an EASD study flags heart risk below GLP-1 cutoffs, and Jena chemists map a peptide's function switch.
Read digest →The CHMP backs moving Oncopeptides' Pepaxti to third-line myeloma, and Boehringer funds a three-year WHO Foundation obesity program.
Read digest →Novo licenses Nanexa's PharmaShell for monthly or quarterly peptide shots, Roche reports enicepatide Phase 2 data, and Avacta details a pancreatic cancer PDC.
Read digest →FDA approves Lilly's once-weekly insulin Onswik, a natural peptide curbs Alzheimer's pathology in mice, and a jury awards Nektar $90M against Lilly.
Read digest →FDA approves Lantheus's BRAVNETSA as a Lutathera equivalent, warns Empower Pharmacy over compounded GLP-1 copies, and Viking prices a $500M raise.
Read digest →Zealand and Roche start a 7,000-person petrelintide Phase 3, sefaxersen hits its IgAN Phase 3 goal, and AC Immune's peptide vaccine clears a Parkinson's test.
Read digest →J&J's oral IL-23R peptide icotrokinra wins EU approval, barzolvolimab hits both Phase 3 CSU trials, and VK2735 keeps up to 97% of weight loss on maintenance.
Read digest →